Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK ALK F1174V |
| Therapy | Entrectinib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK F1174V | Advanced Solid Tumor | resistant | Entrectinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174V were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640). | 33627640 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33627640) | Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer. | Full reference... |